RTX-IL-12

N/A

Report date: 2023/03/05 18:10:20

Base Information

Drug NameRTX-IL-12
Drug Alias NameRTX-IL-12mRBC-IL-12
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionNatural killer cells stimulantsCell replacementsT lymphocytes stimulants +[4] 
TargetsInterleukin-12
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRubius Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRubius Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A